Loading clinical trials...
Loading clinical trials...
A Multi-centre, Double-blind, Double-dummy, Placebo Controlled Parallel Group Randomized Phase IIb Proof of Concept Study With 3 Oral Dose Groups of AZD3480 or Donepezil During 12 Weeks Treatment in Patients With Alzheimer's Disease
The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with mild or moderate Alzheimer's disease, to assess the safety and tolerability of ZAD3480 and to define the optimal dose(s) to be used in future trials.
Age
60 - 85 years
Sex
ALL
Healthy Volunteers
No
Research Site
Graz, Osterreich, Austria
Research Site
Innsbruck, Osterreich, Austria
Research Site
Vienna, Osterreich, Austria
Research Site
Linz, Austria
Research Site
Aalst, Belgium, Belgium
Research Site
Antwerp, Belgium, Belgium
Research Site
Hasselt, Belgium, Belgium
Research Site
Leuven, Belgium, Belgium
Research Site
Sint-Truiden, Belgium, Belgium
Research Site
Pleven, Bulgaria
Start Date
July 1, 2007
Primary Completion Date
August 1, 2008
Completion Date
August 1, 2008
Last Updated
July 23, 2014
659
ACTUAL participants
AZD3480
DRUG
Donepezil
DRUG
Lead Sponsor
AstraZeneca
NCT04123314
NCT07178210
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions